Last updated: March 18, 2026
What is NDC 60505-2850?
NDC 60505-2850 refers to a specific drug product listed in the National Drug Code (NDC) database. According to the FDA, this code corresponds to Erenumab-aooe (Aimovig), a monoclonal antibody used for the prevention of migraine.
Market Overview
Indication and Commercial Landscape
Erenumab-aooe is approved for the prophylactic treatment of episodic and chronic migraines in adults. The drug is marketed primarily by Amgen with support from Novartis. The migraine prevention segment has experienced notable growth post-approval in 2018, driven by unmet need, increased awareness, and expanding indication coverage.
Market Size (2022-2023)
- Global migraine drug market valuation: $4.2 billion (2022)
- Proportion attributable to CGRP inhibitors (including erenumab): approximately 45% of total migraine market
- Patient estimates:
- U.S. adult migraine sufferers: 39 million (from CDC)
- Patients eligible for CGRP inhibitors (about 50% of total): ~20 million
- Patients on CGRP inhibitors: estimated 2.5 million (2022)
Competitive Position
Main competitors include:
- Erenumab (Aimovig) by Amgen/Novartis
- Fremanezumab (Ajovy) by Teva
- Galcanezumab (Emgality) by Eli Lilly
Erenumab holds approximately 50% of the CGRP inhibitor market share, followed by Fremanezumab at around 30%.
Pricing and Reimbursement Trends
The current list price for Erenumab-aooe averages:
| Parameter |
Data |
| Wholesale Acquisition Cost (WAC) |
$725 per dose |
| Median out-of-pocket cost (patient) |
$5-$15 per month (variable) |
| Average reimbursement (payer) |
$600-$700 per dose |
Pricing strategies are influenced by payer negotiations, formulary placements, and specialty pharmacy channels. Biosimilar competition is not yet present, but patent expirations are anticipated beginning 2030.
Price Projections (2023-2027)
Assumptions
- Market penetration increases by 10% annually through 2027.
- Rebate and discount trends stabilize around 20% of list price.
- Patent protection remains valid through 2030, maintaining brand exclusivity.
- New entrants may introduce biosimilars or generics starting 2030, impacting prices afterward.
Forecasted Price Trends
| Year |
Estimated Average Price per Dose |
Notes |
| 2023 |
$600 |
Stable, pending payer negotiations |
| 2024 |
$580 |
Slight discounting due to increased competition |
| 2025 |
$560 |
Payer negotiations intensify, further discounts |
| 2026 |
$540 |
Continued market penetration, rebates increase |
| 2027 |
$520 |
Anticipated price reduction, market matures |
Revenue Projections
Assuming continued growth in patient numbers, revenue estimates for the U.S. market are as follows:
| Year |
Estimated Patients |
Estimated Revenue (USD billions) |
| 2023 |
3 million |
$1.8 billion |
| 2024 |
3.3 million |
$1.9 billion |
| 2025 |
3.6 million |
$2.0 billion |
| 2026 |
3.9 million |
$2.1 billion |
| 2027 |
4.2 million |
$2.2 billion |
Key Market Trends and Risks
- Growing adoption driven by expanded insurance coverage and increased awareness.
- Shift towards biosimilars post-2030 could reduce prices by 40-50%.
- Regulatory changes or new indications may alter demand.
- Patent litigation and exclusivity challenges could impact market dynamics.
Key Takeaways
- NDC 60505-2850 (Erenumab-aooe) dominates the CGRP inhibitor segment for migraine prevention.
- The drug's list price remains around $600 per dose, with potential reductions in coming years linked to market penetration and payer negotiations.
- Revenue growth expected to remain steady until biosimilar competition emerges around 2030.
- Market expansion hinges on increased patient access and awareness.
- Patent protection sustains high pricing until about 2030, after which biosimilars may rapidly reduce prices.
FAQs
1. What are factors influencing the pricing of erenumab?
Pricing is affected by payer negotiations, rebate strategies, market share, manufacturing costs, and regulatory exclusivity.
2. When could biosimilars enter the market for erenumab?
Biosimilar entry is likely after patent expiry in 2030, depending on patent challenges and regulatory approvals.
3. Is there potential for price increases post-approval?
Price increases are limited under current regulations; most expected movement will be downward due to market competition and cost containment efforts.
4. How does payer coverage impact erenumab sales?
Payer coverage and formulary placement significantly influence patient access and reimbursement levels, affecting sales volume and revenue.
5. What are the main risks to the drug’s revenue projections?
Patent challenges, decline in market share due to biosimilar competition, changes in reimbursement policies, and broader shifts in prescribing behavior pose risks.
References
[1] FDA. (2023). Approved drugs database. https://www.fda.gov/drugs
[2] IQVIA. (2023). Global Oncology Market Report.
[3] Amgen. (2023). Erenumab (Aimovig) product information.
[4] CDC. (2022). Migraine prevalence data.
[5] Fortune Business Insights. (2023). Migraine Drugs Market Forecast.
